Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis

A randomized, placebo‐controlled trial of beloranib for the treatment of hypothalamic injury‐associated obesity

“…In particular, hsCRP was extremely elevated at baseline in patients with HIAO (mean 19.9 mg/L), greater than 3 times higher than that observed in patients with other chronic diseases such as exogenous obesity, T2D and polycystic ovary syndrome. [18][19][20][21][22][23] Elevated hsCRP is associated with development of cardiovascular disease and diabetes. 24,25 hsCRP levels fell rapidly at the onset of beloranib treatment (Figure 2), followed by a rapid rise after cessation of treatment, suggesting that beloranib may exert salutary effects on hsCRP that are independent of weight loss.…”

Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes

“…Lifestyle modifications remain the easiest step to reduce the risk of obesity and hepatic steatosis. Medications such as valsartan in adolescents with T1D [68] or pioglitazone with and without fenofibrate in T2D [5, 69, 70, 71] were observed to reduce fetuin A levels [72], with variable effects of metformin [69, 70, 72]. Under certain living and dietary habits, therapeutic interventions targeting fetuin A may also be useful in T1D.…”

Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery

“…6,[30][31][32] Furthermore, a fall in serum fetuin-A levels has been shown after administration of TG-lowering medications, such as fenofibrate, n-3 polyunsaturated fatty acids and niacin. [33][34][35] Kaushik et al reported that the niacininduced change in circulating fetuin-A was positively correlated with the change in TG. 35 However, the relationship of the change in circulating fetuin-A with the change in TG during a weight loss intervention has not been previously investigated.…”